Asia Pacific Cell Therapy Market Size & Outlook, 2023-2030
The cell therapy market in Asia Pacific is expected to reach a projected revenue of US$ 2,774.9 million by 2030. A compound annual growth rate of 22.6% is expected of Asia Pacific cell therapy market from 2024 to 2030.
Revenue, 2023 (US$M)
$667.9
Forecast, 2030 (US$M)
$2,774.9
CAGR, 2024 - 2030
22.6%
Report Coverage
Asia Pacific
Asia Pacific Cell Therapy Market, 2018-2030 (US$M)
Global Market
Related Markets
Asia Pacific cell therapy market highlights
- The Asia Pacific cell therapy market generated a revenue of USD 667.9 million in 2023.
- The market is expected to grow at a CAGR of 22.6% from 2024 to 2030.
- In terms of segment, autologous therapies was the largest revenue generating therapy type in 2023.
- Autologous Therapies is the most lucrative therapy type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 667.9 million |
| Market revenue in 2030 | USD 2,774.9 million |
| Growth rate | 22.6% (CAGR from 2023 to 2030) |
| Largest segment | Autologous therapies |
| Fastest growing segment | Autologous Therapies |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Allogeneic Therapies, Autologous Therapies |
| Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 14.1% of the global cell therapy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 6,066.1 million by 2030.
Key Regions:U.S., UK, Japan, South Korea, Germany
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Cell Therapy Market Scope
Cell Therapy Market segmentation & scope
Cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Beiersdorf AG | View profile | 21,958 | Unnastrasse 48, Hamburg, Germany, 22529 | www.beiersdorf.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| JCR Pharmaceuticals Co Ltd | View profile | 932 | 3-19 Kasuga-cho, Ashiya, Hyogo, Japan, 659-0021 | www.jcrpharm.co.jp |
| Medipost | View profile | 51-100 | Seongnam, Kyonggi-do, South Korea, Asia | www.medi-post.com/ |
| JW (Cayman) Therapeutics Co Ltd Ordinary Shares | View profile | 398 | No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, China, People's Republic of | www.jwtherapeutics.com |
| Atara Biotherapeutics Inc | View profile | 173 | 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, United States, 91320 | www.atarabio.com |
| Nkarta Inc Ordinary Shares | View profile | 150 | 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080 | www.nkartatx.com |
Asia Pacific Cell Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell Therapy Market Outlook will help companies and investors design strategic landscapes.
Autologous Therapies was the largest segment with a revenue share of 76.34% in 2023.
Horizon Databook has segmented the Asia Pacific cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Cell Therapy Market Therapy Type Outlook (Revenue, USD Million , 2018-2030)
- Allogeneic Therapies
- Autologous Therapies
- Asia Pacific Cell Therapy Market Therapeutic Area Outlook (Revenue, USD Million , 2018-2030)
- Oncology
- Cardiovascular Disease (CVD)
- Musculoskeletal Disorders
- Dermatology
- Others
Reasons to subscribe to Cell Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell Therapy Market Outlook databook
- Our clientele includes a mix of Cell Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Cell Therapy Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Cell Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Asia Pacific Cell Therapy Market, 2018-2030 (US$M)
Asia Pacific cell therapy market statistics, by therapy type, 2018-2030 (US$M)
